Obesity & ROSE-010:
The Future of Weight Loss Maintenance

The GLP-1 Dilemma: Maintaining Weight Loss & Seeking Alternative Weight Loss Options

GLP-1 therapies have helped millions lose weight, yet 60-85% of patients discontinue within two years due to:

  • Tolerability Issues – Over 50% of GLP-1 patients stop due to nausea, vomiting, or GI side effects
  • Insurance & Cost Barriers – Insurance coverage remains inconsistent, limiting long-term access
  • Reaching Their Goal – Many patients lose their desired weight and no longer need daily or weekly injections

The Problem? Most weight regain occurs within 12-18 months of stopping GLP-1 therapy. Sustaining weight loss requires appetite control, behavioral changes, and flexible solutions—but long-acting GLP-1s often do not meet peoples needs for weight loss maintenance.

People desire options for various amounts of weight loss & improved tolerability:
  • Studies show that as little as 5% weight loss significantly decreases risk factors for cardiometabolic disease
  • Reducing hunger promotes food-related behavioral modification through satiety
  • People desire multiple options for weight loss support
We need a smarter approach to Weight Loss Management

ROSE-010 is a first-of-its-kind, fast-acting, short-duration GLP-1 designed to support weight loss maintenance. Unlike traditional long-acting GLP-1s, ROSE-010 is taken on-demand, around meals, offering flexible hunger suppression without continuous drug exposure.

Key Clinical Findings from Rose Pharma Studies:
  • Proven Appetite Suppression: Completed proof of concept study, demonstrated that ROSE-010 significantly reduces food consumption and slows gastric emptying
  • Rapid Onset, Short Duration: Begins working within 20 minutes and clears within a few hours, minimizing side effects
  • Reduced GI Side Effects: Unlike long-acting GLP-1s, ROSE-010’s shorter half-life lowers the period of nausea and GI distress
  • Improved Tolerability: Targets appetite without prolonged drug exposure, making it an ideal maintenance therapy

Why the Market Needs ROSE-010
  • 60-85% of GLP-1 patients need an effective weight loss maintenance strategy
  • Current solutions focus on weight loss—People need long-term weight loss management options
  • ROSE-010 offers a flexible, meal-time approach to prevent weight regain

Real-world data shows that long-term GLP-1 adherence is low—yet patients need tools to sustain their progress. ROSE-010 fills this gap, offering a patient-friendly, meal-time GLP-1 option that aligns with real-world weight management needs.

The future of obesity treatment isn’t just about losing more weight—it’s about keeping it off. Rose Pharma Inc is developing ROSE-010 to be the solution.